

## Complementary Medicines References

1. Therapeutic Goods Administration. Complementary medicines. 2020. At: [www.tga.gov.au/complementary-medicines](http://www.tga.gov.au/complementary-medicines)
2. NPS MedicineWise. Complementary medicines explained. 2016. At: [www.nps.org.au/consumers/complementary-medicines-explained](http://www.nps.org.au/consumers/complementary-medicines-explained)
3. National Health and Medical Research Council. Talking with your patients about complementary medicine - a resource for clinicians. Canberra: NHMRC; 2014. At: [www.nhmrc.gov.au/sites/default/files/2018-03/complementary-medicine-resource-clinicians.pdf](http://www.nhmrc.gov.au/sites/default/files/2018-03/complementary-medicine-resource-clinicians.pdf)
4. Cancer Council Australia. Position statement: complementary and alternative therapies. 2013. At: [http://wiki.cancer.org.au/policy/Position\\_statement\\_-\\_Complementary\\_and\\_alternative\\_therapies](http://wiki.cancer.org.au/policy/Position_statement_-_Complementary_and_alternative_therapies)
5. Therapeutic Goods Administration. Overview of the regulation of listed medicines and registered complementary medicines. Australian regulatory guidelines. Canberra: TGA; 2020. At: [www.tga.gov.au/resource/overview-regulation-listed-medicines-and-registered-complementary-medicines](http://www.tga.gov.au/resource/overview-regulation-listed-medicines-and-registered-complementary-medicines)
6. World Health Organization. WHO traditional medicine strategy 2014–2023. Geneva: WHO; 2013. At: [www.who.int/traditional-complementary-integrative-medicine/publications/trm\\_strategy14\\_23/en/](http://www.who.int/traditional-complementary-integrative-medicine/publications/trm_strategy14_23/en/)
7. Saper R. Overview of herbal medicine and dietary supplements. 2020. At: [www.uptodate.com](http://www.uptodate.com)
8. Therapeutic Goods Administration. Equivalence of herbal extracts in complementary medicines. 2011. At: [www.tga.gov.au/equivalence-herbal-extracts-complementary-medicines](http://www.tga.gov.au/equivalence-herbal-extracts-complementary-medicines)
9. Heinrich M. Quality and safety of herbal medical products: regulation and the need for quality assurance along the value chains. *Br J Clin Pharmacol* 2015;80(1):62–66.
10. Byard RW, Musgrave I, Maker G, et al. What risks do herbal products pose to the Australian community?. *Med J Aust* 2017;206(2):86–90.
11. Braun L, Cohen M. Herbs and natural supplements: an evidence-based guide. 4th edn. Chatswood: Elsevier; 2015.
12. Royal Pharmaceutical Society of Great Britain. Herbal medicines. 4th edn. London: Pharmaceutical Press; 2013.
13. Therapeutic Goods Administration. Listed medicine presentation and labels: Australian regulatory guidance. Canberra: TGA; 2020. At: [www.tga.gov.au/resource/listed-medicine-presentation-and-labels](http://www.tga.gov.au/resource/listed-medicine-presentation-and-labels)
14. Therapeutic Goods Administration. Approved names for herbal ingredients. 2020. At: [www.tga.gov.au/approved-names-herbal-ingredients](http://www.tga.gov.au/approved-names-herbal-ingredients)
15. Australian Government. Therapeutic Goods Advertising Code (No. 2). 2018. At: [www.tga.gov.au/publication/therapeutic-goods-advertising-code](http://www.tga.gov.au/publication/therapeutic-goods-advertising-code)
16. Myers S, Cheras P. The other side of the coin: safety of complementary and alternative medicine. *Med J Aust* 2004;181(4):222–5.
17. Moses G, McGuire T. Drug interactions with complementary medicines. *Aust Prescr* 2010;33:177–80.
18. Lim R, Semple S, Ellett L, et al. Medicine safety: take care. Canberra: Pharmaceutical Society of Australia; 2019.
19. Memorial Sloan Kettering Cancer Center. Integrative medicine. At: [www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine](http://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine)

20. National Center for Complementary and Integrative Health. Herbs at a glance. At: [www.nccih.nih.gov/health/herbsataglance](http://www.nccih.nih.gov/health/herbsataglance)
21. Frawley J, Adams J, Sibbritt D, et al. Prevalence and determinants of complementary and alternative medicine use during pregnancy: results from a nationally representative sample of Australian pregnant women. *Aust N Z J Obstet Gynaecol* 2013;53(4):347–52.
22. Pharmaceutical Society of Australia. Complementary medicines: position statement. Canberra: PSA; 2018. At: <https://my.psa.org.au/s/article/complementary-medicines>
23. Pharmaceutical Society of Australia. Professional practice standards. Version 5. Canberra: PSA; 2017.
24. Pharmaceutical Society of Australia. Code of ethics for pharmacists. Canberra: PSA; 2017.
25. National Health and Medical Research Council. Statement on homeopathy. Canberra: NHMRC; 2015. At: [www.nhmrc.gov.au/about-us/resources/homeopathy](http://www.nhmrc.gov.au/about-us/resources/homeopathy)
26. Therapeutic Research Center. Natural medicines. 2020. At: <https://naturalmedicines.therapeuticresearch.com>
27. Woollorton E. Too much of a good thing? Toxic effects of vitamin and mineral supplements. *CMAJ* 2003;169(1):47–8.
28. Therapeutic Research Center. Natural medicines: COVID-19 advisory. 2020. At: <https://naturalmedicines.therapeuticresearch.com/tools/covid-19-advisory.aspx>
29. National Center for Complementary and Integrative Health. In the news: coronavirus and “alternative” treatments. 2020. At: [www.nccih.nih.gov/health/in-the-news-coronavirus-and-alternative-treatments](http://www.nccih.nih.gov/health/in-the-news-coronavirus-and-alternative-treatments)
30. Coon JT, Ernst E. *Andrographis paniculata* in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. *Planta Med* 2004;70(4):293–8.
31. Hu X-Y, Wu R-H, Logue M, et al. *Andrographis paniculata* (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis. *PloS ONE* 2017;12(8):e0181780.
32. Therapeutic Goods Administration. *Andrographis paniculata* safety advisory—potential to change sense of taste. 2020. At: [www.tga.gov.au/alert/andrographis-paniculata](http://www.tga.gov.au/alert/andrographis-paniculata)
33. Therapeutic Goods Administration. Products containing *Andrographis paniculata*: safety advisory—risk of allergic reactions. 2015. At: [www.tga.gov.au/alert/products-containing-andrographis-paniculata](http://www.tga.gov.au/alert/products-containing-andrographis-paniculata)
34. Williamson E, Driver S, Baxter K, eds. *Stockley’s herbal medicines interactions*. 2nd edn. London: Pharmaceutical Press; 2013.
35. Memorial Sloan Kettering Cancer Center. About herbs, botanicals and other products. 2020. At: [www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs](http://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs)
36. Ma HY, Sun DX, Cao YF, et al. Herb-drug interaction prediction based on the high specific inhibition of andrographolide derivatives towards UDP-glucuronosyltransferase (UGT) 2B7. *Toxicol Appl Pharmacol* 2014;277(1):86–94.
37. Wider B, Pittler MH, Thompson-Coon J, et al. Artichoke leaf extract for treating hypercholesterolaemia. *Cochrane Database of Systematic Reviews* 2013, Issue 3.
38. Sahebkar A, Pirro M, Banach M, et al. Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. *Crit Rev Food Sci Nutr* 2018;58(15):2549–2556.

39. European Medicines Agency. European Union herbal monograph on *Cynara cardunculus* L. (syn. *Cynara scolymus* L.), folium. 2018. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cynara-cardunculus-l-syn-cynara-scolymus-l-folium\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cynara-cardunculus-l-syn-cynara-scolymus-l-folium_en.pdf)
40. Chen MH, May BH, Zhou IW, et al. Integrative medicine for relief of nausea and vomiting in the treatment of colorectal cancer using oxaliplatin-based chemotherapy: a systematic review and meta-analysis. *Phytother Res* 2016;30(5):741–53.
41. Lin S, An X, Guo Y, et al. Meta-analysis of astragalus-containing traditional Chinese medicine combined with chemotherapy for colorectal cancer: Efficacy and safety to tumor response. *Front Oncol* 2019;9:749.
42. Tian QE, De Li H, Yan M, et al. Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitro. *BMC Complement Altern Med* 2012;12:94.
43. Zhou Q, Ye Z, Ruan Z, et al. Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. *J Ethnopharmacol* 146(3):744–9.
44. Brayfield A, ed. Martindale: the complete drug reference. London: Pharmaceutical Press. At: [www.medicinescomplete.com](http://www.medicinescomplete.com).
45. Fuchikami H, Satoh H, Tsujimoto M, et al. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. *Drug Metab Dispos* 2006;34(4):577–82.
46. Drugs and lactation database (LactMed). Bilberry. 2020. At: [www.ncbi.nlm.nih.gov/books/NBK501825/](http://www.ncbi.nlm.nih.gov/books/NBK501825/)
47. Beer AM, Neff A. Differentiated evaluation of extract-specific evidence on *Cimicifuga racemosa*'s efficacy and safety for climacteric complaints. *Evid Based Complement Alternat Med* 2013; Epub 2013 Aug 25.
48. Fritz H, Seely D, McGowan J, et al. Black cohosh and breast cancer: a systematic review. *Integr Cancer Ther* 2014;13(1):12–29.
49. Franco OH, Chowdhury R, Troup J, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. *JAMA* 2016;315(23):2554–63.
50. Sarri G, Pedder H, Dias S, et al. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. *BJOG* 2017;124(10):1514–1523.
51. European Medicines Agency. European Union herbal monograph on *Cimicifuga racemosa* (L.) Nutt., rhizoma. 2018. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf)
52. Therapeutic Goods Administration. Black cohosh (*Cimicifuga racemosa*). 2007. At: [www.tga.gov.au/alert/black-cohosh-cimicifuga-racemosa](http://www.tga.gov.au/alert/black-cohosh-cimicifuga-racemosa)
53. Leach MJ, Moore V. Black cohosh (*Cimicifuga* spp.) for menopausal symptoms. *Cochrane Database of Systematic Reviews* 2012, Issue 9.
54. Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. *Breast Cancer Res Treat* 2005;90(3):233–9.
55. Einbond LS, Shimizu M, Nuntanakorn P, et al. Actein and a fraction of black cohosh potentiate antiproliferative effects of chemotherapy agents on human breast cancer cells. *Planta Med* 2006;72(13):1200–6.

56. Royal Women's Hospital. Pregnancy and breastfeeding medicines guide. 2020. At: [www.thewomenspbmg.org.au](http://www.thewomenspbmg.org.au)
57. Oltean H, Robbins C, van-Tulder MW, et al. Herbal medicine for low-back pain. *Cochrane Database of Systematic Reviews* 2014, Issue 12.
58. Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. *Ann Intern Med* 2014;161(9):639–49.
59. van Nooten F, Treur M, Pantiri K, et al. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: A systematic literature review and network meta-analysis. *Clin Ther* 2017;39(4):787–803.
60. Derry S, Rice AS, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2017, Issue 1.
61. Yong YL, Tan LT, Ming LC, et al. The effectiveness and safety of topical capsaicin in postherpetic neuralgia: a systematic review and meta-analysis. *Front Pharmacol* 2016;7:538.
62. eMIMS cloud. Sydney: MIMS Australia; 2020.
63. Hakas JF. Topical capsaicin induces cough in patient receiving ACE inhibitor. *Ann Allergy* 1990;65:322–3.
64. Zhu HD, Gu N, Wang M, et al. Effects of capsaicin on rat cytochrome P450 isoforms CYP1A2, CYP2C19, and CYP3A4. *Drug Dev Ind Pharm* 2015;41(11):1824–8.
65. Han Y, Tan TM, Lim LY. Effects of capsaicin on P-gp function and expression in Caco-2 cells. *Biochem Pharmacol* 2006;71(12):1727–34.
66. Derry S, Sven-Rice A, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2013, Issue 2.
67. Puig L, de-Moraqas JM. Enhancement of PUVA phototoxic effects following celery ingestion: cool broth also can burn. *Arch Dermatol* 1994;130(6):809–10.
68. Peterson S, Lampe JW, Bammler TK, et al. Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. *Food Chem Toxicol* 2006;44(9):1474–84.
69. Moses G. Thyroxine interacts with celery seed tablets? *Aust Prescr* 2001;24:6–7.
70. Ottillinger B, Storr M, Malfertheiner P, et al. STW 5 (Iberogast): a safe and effective standard in the treatment of functional gastrointestinal disorders. *Wien Med Wochenschr* 2013;163(3–4):65–72.
71. Melzer J, Rösch W, Reichling J, et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). *Aliment Pharmacol Ther* 2004;20(11–12):1279–87.
72. eTG complete. Melbourne: Therapeutic Guidelines; 2020.
73. Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. *Aliment Pharmacol Ther* 2004;19(3):271–9.
74. Segal R, Pilote L. Warfarin interaction with *Matricaria chamomilla*. *CMAJ* 2006;174(9):1281–2.
75. Kassi E, Papoutsis Z, Fokialakis N, et al. Greek plant extracts exhibit selective estrogen receptor modulator (SERM)-like properties. *J Agric Food Chem* 2004;52(23):6956–61.

76. Sridharan S, Archer N, Manning N. Premature constriction of the fetal ductus arteriosus following the maternal consumption of camomile herbal tea. *Ultrasound Obstet Gynecol* 2009;34(3):358–9.
77. Ooi SL, Watts S, McLean R, et al. Vitex agnus-castus for the treatment of cyclic mastalgia: A systematic review and meta-analysis. *J Womens Health (Larchmt)* 2020;29(2):262–278.
78. van Die MD, Burger HG, Teede HJ, et al. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. *Planta Med* 2013;79(7):562–75.
79. Verkaik S, Kamperman A, van Westrhenen A, et al. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2017;217(2):150–166.
80. Csupor D, Lantos T, Hegyi P, et al. Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind randomised controlled trials. *Complement Ther Med* 2019;47:102190.
81. Braun L, Cohen M. Herbs and natural supplements: an evidence based guide. 3rd edn. Elsevier; 2010.
82. Therapeutic Goods Administration. Vitex agnus-castus safety advisory–potential for interaction with oral contraceptives. 2019. At: [www.tga.gov.au/alert/vitex-agnus-castus](http://www.tga.gov.au/alert/vitex-agnus-castus)
83. Dugoua JJ, Seely D, Perri D, et al. Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation. *Can J Clin Pharmacol* 2008;15(1):e74–9.
84. Buckingham R, ed. Martindale: the complete drug reference. London: Pharmaceutical Press; 2020.
85. World Anti-Doping Agency. List of prohibited substances and methods. 2020. At: [www.wada-ama.org/en/content/what-is-prohibited](http://www.wada-ama.org/en/content/what-is-prohibited)
86. Banach M, Serban C, Ursoniu S, et al. Statin therapy and plasma coenzyme Q10 concentrations: a systematic review and meta-analysis of placebo-controlled trials. *Pharmacol Res* 2015;99:329–36.
87. Bank G, Kagan D, Madhavi D. Coenzyme Q10: clinical update and bioavailability. *J Evid Based Complementary Altern Med* 2011;16(2):129–37.
88. Zhang S, Yang K, Zeng L, et al. Effectiveness of coenzyme Q10 supplementation for type 2 diabetes mellitus: A systematic review and meta-analysis. *Int J Endocrinol* 2018;6484839.
89. Gholnari T, Aghadavod E, Soleimani A, et al. The effects of coenzyme Q10 supplementation on glucose metabolism, lipid profiles, inflammation, and oxidative stress in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. *J Am Coll Nutr* 2018;37(3):188–193.
90. Madmani ME, Yusuf Solaiman A, Tamr Agha K, et al. Coenzyme Q10 for heart failure. *Cochrane Database of Systematic Reviews* 2014, Issue 6.
91. Lei L, Liu Y. Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials. *BMC Cardiovasc Disord* 2017;17:196.
92. Ho MJ, Li ECK, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. *Cochrane Database of Systematic Reviews* 2016, Issue 3.
93. Parohan M, Sarraf P, Javanbakht M, et al. Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials. *Nutr Neurosci* 2020;23(11):868–75.
94. Negida A, Menshawy A, Ashal GE, et al. Coenzyme Q10 for patients with Parkinson's disease: a systematic review and meta-analysis. *CNS Neurol Disord Drug Targets* 2016;15(1):45–53.
95. Zhu ZG, Sun MX, Zhang WL, et al. The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials. *Neurol Sci* 2017;38(2):215–24.

96. Taylor B. Does coenzyme Q10 supplementation mitigate statin-associated muscle symptoms?. *Am J Cardiovasc Drugs* 2018;18(2):75–82.
97. Qu H, Guo M, Chai H, et al. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. *J Am Heart Assoc* 2018;7(19):e009835.
98. Kennedy C, Koller Y, Surkova E. Effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: a systematic review and meta-analysis. *Atherosclerosis* 2020;299:1–8.
99. Baskaran R, Shanmugam S, Nagayya-Sriraman S, et al. The effect of coenzyme Q10 on the pharmacokinetic parameters of theophylline. *Arch Pharm Res* 2008;31(7):938–44.
100. Therapeutic Goods Administration. Complementary Medicines Evaluation Committee extracted ratified minutes, 11th meeting, 24 February. 1999. At: [www.tga.gov.au/sites/default/files/cmec-minutes-11.pdf](http://www.tga.gov.au/sites/default/files/cmec-minutes-11.pdf)
101. DiNicolantonio JJ, Bhutani J, McCarty MF, et al. Coenzyme Q10 for the treatment of heart failure: a review of the literature. *Open Heart* 2015;2:e000326.
102. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-Induced myopathy: a meta-analysis of randomized controlled trials. *Mayo Clin Proc* 2015;90(1):24–34.
103. Beecher G. Overview of dietary flavonoids: nomenclature, occurrence and intake. *J Nutr* 2003;133(10):3248S–3254S.
104. Liska DJ, Kern HJ, Maki KC. Cranberries and urinary tract infections: how can the same evidence lead to conflicting advice?. *Adv Nutr* 2016;7(3):498–506.
105. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. *Cochrane Database of Systematic Reviews* 2012, Issue 10.
106. Durham SH, Stamm PL, Eiland LS. Cranberry products for the prophylaxis of urinary tract infections in pediatric patients. *Ann Pharmacother* 2015;49(12):1349–56.
107. Luis A, Domingues F, Pereira L, et al. Can cranberries contribute to reduce the incidence of urinary tract infections? A systematic review with meta-analysis and trial sequential analysis of clinical trials. *J Urol* 2017;198(3):614–21.
108. Fu Z, Liska D, Talan D, et al. Cranberry reduces the risk of urinary tract infection recurrence in otherwise healthy women: a systematic review and meta-analysis. *J Nutr* 2017;147(12):2282–8.
109. Jepson RG, Mihaljevic L, Craig JC. Cranberries for treating urinary tract infections. *Cochrane Database of Systematic Reviews* 1998, Issue 4.
110. Dave A, Samuel J. Suspected interaction of cranberry juice extracts and tacrolimus serum levels: a case report. *Cureus* 2016;8(5):e610.
111. Mohammed Abdul MI, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. *Br J Pharmacol* 2008;154(8):1691–700.
112. Dugoua J, Seely D, Perri D, et al. Safety and efficacy of cranberry (*Vaccinium macrocarpon*) during pregnancy and lactation. *Can J Clin Pharmacol* 2008;15(1):e80–6.
113. Davis SR, Panjari M, Stanczyk FZ. DHEA replacement for postmenopausal women. *J Clin Endocrinol Metab* 2011;96(6):1642–53.
114. Therapeutic Goods Administration. Personal importation scheme. 2015. At: [www.tga.gov.au/personal-importation-scheme](http://www.tga.gov.au/personal-importation-scheme)
115. Nagels HE, Rishworth JR, Siristatidis CS, et al. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. *Cochrane Database of Systematic Reviews* 2015, Issue 11.

116. Schwarze J, Canales J, Crosby J, et al. DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: a systematic review and meta-analysis. *JBRA Assist Reprod* 2018;22(4):369–74.
117. Peixoto de Souza C, Grande A, Mallman M, et al. Dehydroepiandrosterone (DHEA) for depression: a systematic review and meta-analysis. *CNS Neurol Disord Drug Targets* 2018;17(9):706–11.
118. Scheffers CS, Armstrong S, Cantineau AE, et al. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. *Cochrane Database of Systematic Reviews* 2015, Issue 1.
119. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. *Menopause* 2018;25(11):1339–53.
120. Corrigan AB. Dehydroepiandrosterone and sport. *Med J Aust* 1999;171(4):206–8.
121. Jenkinson D, Harbert A. Supplements and sports. *Am Fam Physician* 2008;78(9):1039–46.
122. Thompson R, Carlson M. Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products. *J AOAC Int* 2000;83(4):847–57.
123. Kim C, Halter JB. Endogenous sex hormones, metabolic syndrome, and diabetes in men and women. *Curr Cardiol Rep* 2014;16(4):467.
124. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. *J Clin Endocrinol Metab* 1997;82(10):3498–505.
125. Brien S, Lewith GT, McGregor G. Devil's claw (*Harpagophytum procumbens*) as a treatment for osteoarthritis: a review of efficacy and safety. *J Altern Complement Med* 2006;12(10):981–93.
126. Chrubasik JE, Roufogalis BD, Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. *Phytother Res* 2007;21(7):675–83.
127. Devil's claw root: ulcers and gastrointestinal bleeding?. *Prescrire Int* 2013;22(144):296.
128. Cuspidi C, Sala C, Tadic M, et al. Systemic hypertension induced by *Harpagophytum procumbens* (devil's claw): a case report. *J Clin Hypertens (Greenwich)* 2015;17(11):908–10.
129. Carvalho R, Donadel C, Cortez A, et al. Syndrome of inappropriate antidiuretic hormone secretion induced by the phytotherapy *Harpagophytum procumbens*: case report. *J Bras Nefrol* 2017;39(1):79–81.
130. Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). *Drug Saf* 1997;17:342–56.
131. Romiti N, Tramonti G, Corti A, et al. Effects of devil's claw (*Harpagophytum procumbens*) on the multidrug transporter ABCB1/P-glycoprotein. *Phytomedicine* 2009;16(12):1095–100.
132. Zielinsky P, Busato S. Prenatal effects of maternal consumption of polyphenol-rich foods in late pregnancy upon fetal ductus arteriosus. *Birth Defects Res C Embryo Today* 2013;99(4):256–74.
133. Shou C, Li J, Liu Z. Complementary and alternative medicine in the treatment of menopausal symptoms. *Chin J Integr Med* 2011;17(12):883–8.
134. Hann S, Park Y, Im S, et al. Angelica-induced phytophotodermatitis. *Photodermatol Photoimmunol Photomed* 1991;8(2):84–85.
135. Yu C, Chai X, Yu L, et al. Identification of novel pregnane X receptor activators from traditional Chinese medicines. *J Ethnopharmacol* 2011;136(1):137–43.

136. Seviour DK, Hokkanen J, Tolonen A, et al. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. *Xenobiotica* 2010;40(4):245–54.
137. Karsch-Völk M, Barrett B, Kiefer D, et al. Echinacea for preventing and treating the common cold. *Cochrane Database of Systematic Reviews* 2014, Issue 2.
138. Schapowal A, Klein P, Johnston SL. Echinacea reduces the risk of recurrent respiratory tract infections and complications: a meta-analysis of randomized controlled trials. *Adv Ther* 2015;32(3):187–200.
139. David S, Cunningham R. Echinacea for the prevention and treatment of upper respiratory tract infections: a systematic review and meta-analysis. *Complement Ther Med* 2019;44:18–26.
140. Ardjomand-Woelkart K, Bauer R. Review and assessment of medicinal safety data of orally used echinacea preparations. *Planta Med* 2016;82(1–2):17–31.
141. Mullins R, Heddle R. Adverse reactions associated with echinacea: the Australian experience. *Ann Allergy Asthma Immunol* 2002;88(1):42–51.
142. Gorski JC, Huang SM, Pinto A. The effect of echinacea (*Echinacea purpurea* root) on cytochrome P450 activity in vivo. *Clin Pharmacol Ther* 2004;75(1):89–100.
143. Hermann R, Richter OV. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. *Planta Med* 2012;78(13):1458–77.
144. Liu R, Tam TW, Mao J, et al. The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir. *J Pharm Pharm Sci* 2010;13(1):43–55.
145. Qiang Z, Hauck C, McCoy JA, et al. Echinacea sanguinea and Echinacea pallida extracts stimulate glucuronidation and basolateral transfer of Bauer alkaloids 8 and 10 and ketone 24 and inhibit P-glycoprotein transporter in Caco-2 cells. *Planta Med* 2013;79:266–74.
146. Gurley BJ, Swain A, Williams DK, et al. Gauging the clinical significance of P-glycoprotein-mediated herb–drug interactions: comparative effects of St John’s wort, echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. *Mol Nutr Food Res* 2008;52(7):772–9.
147. Organization of Teratology Information Specialists. Echinacea preparations. 2014. At: <https://mothertobaby.org/fact-sheets/echinacea-preparations-pregnancy/>
148. Heitmann K, Havnen GC, Holst L, et al. Pregnancy outcomes after prenatal exposure to echinacea: the Norwegian Mother and Child Cohort Study. *Eur J Clin Pharmacol* 2016;72(5):623–30.
149. Bamford JTM, Ray S, Musekiwa A, et al. Oral evening primrose oil and borage oil for eczema. *Cochrane Database of Systematic Reviews* 2013, Issue 6.
150. Hooper L, Al-Khudairy L, Abdelhamid A, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2018, Issue 11.
151. Sarayloo K, Najmabadi K, Ghazanfarpour M. Effects of the evening primrose oil on women's mastalgia: a systematic review of randomized controlled trials. *Malaysian Journal of Nursing* 2017;9(2):28–35.
152. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. *J Psychosom Obstet Gynaecol* 2011;32(1):42–51.
153. Cameron M, Gagnier JJ, Chrubasik S. Herbal therapy for treating rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2011, Issue 2.

154. Jalloh M, Gregory P, Hein D, et al. Dietary supplement interactions with antiretrovirals: a systematic review. *Int J STD AIDS* 2017;28(1):4–15.
155. Osman M, Badawi E. Evening primrose oil reducing serum lithium concentration. *Ther Adv Psychopharmacol* 2016;6(5):343–344.
156. Puri BK. The safety of evening primrose oil in epilepsy. *Prostaglandins Leukot Essent Fatty Acids* 2007;77(2):101–3.
157. Dove D, Johnson P. Oral evening primrose oil: its effect on length of pregnancy and selected intrapartum outcomes in low-risk nulliparous women. *J Nurse Midwifery* 1999;44(3):320–4.
158. Wedig KE, Whitsett JA. Down the primrose path: petechiae in a neonate exposed to herbal remedy for parturition. *J Pediatr* 2008;152(1):140.
159. Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. *Cochrane Database of Systematic Reviews* 2015, Issue 4.
160. Lopresti A, Smith S, Drummond P. Herbal treatments for migraine: a systematic review of randomised-controlled studies. *Phytother Res* 2020;34(10):2493–517.
161. Johnson ES, Kadam NP, Hylands DM, et al. Efficacy of feverfew as prophylactic treatment of migraine. *Br Med J (Clin Res Ed)* 1985;291(6495):569–73.
162. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. *Rapid Commun Mass Spectrom* 2004;18(19):2273–81.
163. Nestel P, Clifton P, Colquhoun D, et al. Indications for omega-3 long chain polyunsaturated fatty acid in the prevention and treatment of cardiovascular disease. *Heart Lung Circ* 2015;24(8):769–79.
164. Balk EM, Adams GP, Langberg V, et al. Omega-3 fatty acids and cardiovascular disease: an updated systematic review. Evidence report/technology assessment no. 223. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016.
165. Cholewski M, Tomczykowa M, Tomczyk M. A comprehensive review of chemistry, sources and bioavailability of omega-3 fatty acids. *Nutrients* 2018;10(11):1662.
166. Ulven SM, Holven KB. Comparison of bioavailability of krill oil versus fish oil and health effect. *Vasc Health Risk Manag* 2015;11:511–24.
167. Gunaratne AW, Makrides M, Collins CT. Maternal prenatal and/or postnatal n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood. *Cochrane Database of Systematic Reviews* 2015, Issue 7.
168. Best K, Gold M, Kennedy D, et al. Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: a systematic review and meta-analysis of observational studies and randomized controlled trials. *Am J Clin Nutr* 2016;103:128–43.
169. Singh M, Singh M, Jaiswal N, et al. Prenatal fish oil supplementation for prevention of childhood asthma and allergies: A systematic review and meta-analysis. *Am J Respir Crit Care Med* 2019;199:A7472.
170. Vahdaninia M, Mackenzie H, Dean T, et al.  $\omega$ -3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitisation in offspring: a systematic review and meta-analysis. *Ann Allergy Asthma Immunol* 2019;122(3):302–313. e2.
171. Schindler T, Sinn JKH, Osborn DA. Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy. *Cochrane Database of Systematic Reviews* 2016, Issue 10.
172. Zhang Y, Lin J, Zhou R, et al. Effect of omega-3 fatty acids supplementation during childhood in preventing allergic disease: a systematic review and meta-analysis. *J Asthma* 2020; Epub 2020 Jan 10.

173. Su K, Tseng P, Lin P, et al. Association of use of omega-3 polyunsaturated fatty acids with changes in severity of anxiety symptoms: a systematic review and meta-analysis. *JAMA Netw Open* 2018;1(5):e182327.
174. Chang J, Su K, Mondelli V, et al. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. *Neuropsychopharmacology* 2018;43(3):534–545.
175. Abdullah M, Jowett B, Whittaker P, et al. The effectiveness of omega-3 supplementation in reducing ADHD associated symptoms in children as measured by the Conners' rating scales: A systematic review of randomized controlled trials. *J Psychiatr Res* 2019;110:64–73.
176. National Heart Foundation of Australia. Dietary position statement. Fish, seafood and heart healthy eating. 2015. At: [www.heartfoundation.org.au/for-professionals/food-and-nutrition/position-statements](http://www.heartfoundation.org.au/for-professionals/food-and-nutrition/position-statements)
177. Abdelhamid A, Brown T, Brainard J, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Systematic Reviews* 2020, Issue 3.
178. Cooper RE, Tye C, Kuntsi J, et al. Omega-3 polyunsaturated fatty acid supplementation and cognition: a systematic review and meta-analysis. *J Psychopharmacol* 2015;29(7):753–63.
179. Tan ML, Ho JJ, Teh KH. Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders. *Cochrane Database of Systematic Reviews* 2016, Issue 9.
180. Sydenham E, Dangour AD, Lim WS. Omega-3 fatty acid for the prevention of cognitive decline and dementia. *Cochrane Database of Systematic Reviews* 2012, Issue 6.
181. Burckhardt M, Herke M, Wustmann T, et al. Omega-3 fatty acids for the treatment of dementia. *Cochrane Database of Systematic Reviews* 2016, Issue 4.
182. Alex A, Abbott K, McEvoy M, et al. Long-chain omega-3 polyunsaturated fatty acids and cognitive decline in non-demented adults: a systematic review and meta-analysis. *Nutr Rev* 2020;78(7):563–578.
183. Delgado-Noguera MF, Calvache JA, Bonfill Cosp X, et al. Supplementation with long chain polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child growth and development. *Cochrane Database of Systematic Reviews* 2015, Issue 7.
184. Moon K, Rao SC, Schulzke SM, et al. Longchain polyunsaturated fatty acid supplementation in preterm infants. *Cochrane Database of Systematic Reviews* 2016, Issue 12.
185. Jasani B, Simmer K, Patole SK, et al. Long chain polyunsaturated fatty acid supplementation in infants born at term. *Cochrane Database of Systematic Reviews* 2017, Issue 3.
186. Gould JF, Treyvaud K, Yelland LN, et al. Seven-year follow-up of children born to women in a randomized trial of prenatal DHA supplementation. *JAMA* 2017;317(11):1173–5.
187. Shulkin M, Pimpin L, Bellinger D, et al. n-3 fatty acid supplementation in mothers, preterm infants, and term infants and childhood psychomotor and visual development: a systematic review and meta-analysis. *J Nutr* 2018;148(3):409–418.
188. Bae J, Kim G. Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression. *Nutr Res* 2018;50:1–9.
189. Deane K, Jimoh O, Biswas P, et al. Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials. *Br J Psychiatry* 2019; Epub 2019 Oct 24.
190. Downie L, Ng S, Lindsley K, et al. Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease. *Cochrane Database of Systematic Reviews* 2019, Issue 12.

191. Hill CL, March LM, Aitkin D, et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. *Ann Rheum Dis* 2016;57(1):23–9.
192. Senftleber NK, Nielsen SM, Andersen JR, et al. Marine oil supplements for arthritis pain: a systematic review and meta-analysis of randomized trials. *Nutrients* 2017;9(1):e42.
193. Kuszewski J, Wong R, Howe P. Fish oil supplementation reduces osteoarthritis-specific pain in older adults with overweight/obesity. *Rheumatol Adv Pract* 2020;4(2):rkaa036.
194. Middleton P, Gomersall J, Gould J, et al. Omega-3 fatty acid addition during pregnancy. *Cochrane Database of Systematic Reviews* 2018, Issue 11.
195. James M, Proudman S, Cleland L. Fish oil and rheumatoid arthritis: past, present and future. *Proc Nutr Soc* 2010;69(3):316–23.
196. Miles EA, Calder PC. Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. *Br J Nutr* 2012;107(Suppl 2):S171–84.
197. Lee YH, Bae SC, Song GG. Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. *Arch Med Res* 2012;43(5):356–62.
198. Proudman SM, James MJ, Spargo LD, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. *Ann Rheum Dis* 2013; Epub 2013 Sep 30.
199. Gioxari A, Kaliora A, Marantidou F, et al. Intake of  $\omega$ -3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a systematic review and meta-analysis. *Nutrition* 2018;45:114–24.
200. Therapeutic Goods Administration. Compositional guideline: fish oil—natural. 2012. At: [www.tga.gov.au/compositional-guideline/fish-oil-natural](http://www.tga.gov.au/compositional-guideline/fish-oil-natural)
201. Chang C, Tseng P, Chen N, et al. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. *Prostaglandins Leukot Essent Fatty Acids* 2018;129:1–12.
202. Begtrup KM, Krag AE, Hvas AM. No impact of fish oil supplements on bleeding risk: a systematic review. *Dan Med J* 2017;64(5):A5366.
203. Preston CL, ed. *Stockley's drug interactions*. 12 edn. London: Pharmaceutical Press; 2019. At: [www.medicinescomplete.com/about](http://www.medicinescomplete.com/about)
204. Akedo I, Ishikawa H, Nakamura T, et al. Three cases with familial adenomatous polyposis diagnosed as having malignant lesions in the course of a long-term trial using docosahexanoic acid (DHA)-concentrated fish oil capsules. *Jpn J Clin Oncol* 1998;28(12):762–5.
205. Kelley D, Rudolph I. Effect of individual fatty acids of omega-6 and omega-3 type on human immune status and role of eicosanoid. *Nutrition* 2000;16:143–5.
206. World Health Organization. Marine oil supplementation to improve pregnancy outcomes. 2011. At: [www.who.int/elena/titles/bbc/fish\\_oil\\_pregnancy/en](http://www.who.int/elena/titles/bbc/fish_oil_pregnancy/en)
207. Food Standards Australia New Zealand. Pregnancy and healthy eating. 2016. At: [www.foodstandards.gov.au/consumer/generalissues/pregnancy/Pages/default.aspx](http://www.foodstandards.gov.au/consumer/generalissues/pregnancy/Pages/default.aspx)
208. National Heart Foundation of Australia. Fish and omega-3: questions and answers for health professionals. Canberra: Heart Foundation; 2015. At: [www.heartfoundation.org.au/getmedia/741b352b-1746-48f4-806a-30f55fddfad2/Health\\_Professional\\_QA\\_Fish\\_Omega3\\_Cardiovascular\\_Health.pdf](http://www.heartfoundation.org.au/getmedia/741b352b-1746-48f4-806a-30f55fddfad2/Health_Professional_QA_Fish_Omega3_Cardiovascular_Health.pdf)

209. National Heart Foundation of Australia. Dietary position statement. Dietary fat and heart healthy eating. Canberra: Heart Foundation; 2020. At: [www.heartfoundation.org.au/getmedia/6e89409a-3660-4ce8-81fa-92b113510043/Nutrition\\_Position\\_Statement\\_-\\_DIETARY\\_FAT\\_FINAL-4.pdf](http://www.heartfoundation.org.au/getmedia/6e89409a-3660-4ce8-81fa-92b113510043/Nutrition_Position_Statement_-_DIETARY_FAT_FINAL-4.pdf)
210. Shang A, Cao S, Xu X, et al. Bioactive compounds and biological functions of garlic (*Allium sativum* L.). *Foods* 2019;8(7):246.
211. Kim JY, Kwon O. Garlic intake and cancer risk: an analysis using the Food and Drug Administration's evidence-based review system for the scientific evaluation of health claims. *Am J Clin Nutr* 2009;89(1):257–64.
212. Li W, Zhang J, Ma J, et al. Effects of *Helicobacter pylori* treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. *BMJ* 2019;366:I5016.
213. Zhou X, Qian H, Zhang D, et al. Garlic intake and the risk of colorectal cancer: a meta-analysis. *Medicine* 2020;99:1 (e18575).
214. Lissiman E, Bhasale AL, Cohen M. Garlic for the common cold. *Cochrane Database of Systematic Reviews* 2014, Issue 11.
215. Wang J, Zhang X, Lan H, et al. Effect of garlic supplement in the management of type 2 diabetes mellitus (T2DM): a meta-analysis of randomized controlled trials. *Food Nutr Res* 2017;61(1):1377571.
216. Chan W, McLachlan A, Luca E, et al. Garlic (*Allium sativum* L.) in the management of hypertension and dyslipidemia: a systematic review. *J Herb Med* 2020;19:100292.
217. Ried K. Garlic lowers blood pressure in hypertensive individuals, regulates serum cholesterol, and stimulates immunity: an updated meta-analysis and review. *J Nutr* 2016;146(2):389S–396S.
218. Mohammad Abdul MI, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. *Br J Pharmacol* 2008;154(8):1691–700.
219. Shi S, Klotz U. Drug interactions with herbal medicines. *Clin Pharmacokinet* 2012;51(2):77–104.
220. Shaikh S, Tischer S, Choi E, et al. Good for the lung but bad for the liver? Garlic-induced hepatotoxicity following liver transplantation. *J Clin Pharm Ther* 2017;42(5):646–8.
221. Cho HJ, Yoon IS. Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein. *Evid Based Complement Alternat Med* 2015;2015:736431.
222. Hajda J, Rentsch K, Gubler C, et al. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. *Eur J Pharm Sci* 2010;41(5):729–35.
223. Chan W, McLachlan A, Wheate N, et al. An evaluation of garlic products available in Australian pharmacies: from the label to the laboratory. *J Herb Med* 2018;14:61–7.
224. Rondanelli M, Fossari F, Vecchio V, et al. Clinical trials on pain lowering effect of ginger: a narrative review. *Phytother Res* 2020; 1–14.
225. Sutton M, Mounsey AL, Russell RG. Treatment of motion sickness. *Am Fam Physician* 2012;86(2):192–5.
226. Araya-Quintanilla F, Gutierrez-Espinoza H, Munoz-Yanez M, et al. Effectiveness of ginger on pain and function in knee osteoarthritis: a PRISMA systematic review and meta-analysis. *Pain Physician* 2020;23:e151–61.
227. Matthews A, Haas DM, O'Mathuna DP, et al. Interventions for nausea and vomiting in early pregnancy. *Cochrane Database of Systematic Reviews* 2015, Issue 9.

228. McParlin C, O'Donnell A, Robson S, et al. Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review. *JAMA* 2016;316(13):1392–1401.
229. Khorasani F, Aryan H, Sobhi A, et al. A systematic review of the efficacy of alternative medicine in the treatment of nausea and vomiting of pregnancy. *J Obstet Gynaecol* 2020;40(1):10–19.
230. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol* 2005;59(4):425–32.
231. Egashira K, Sasaki H, Higuchi S, et al. Food-drug interaction of tacrolimus with pomelo, ginger and turmeric juice in rats. *Drug Metab Pharmacokinet* 2012;27(2):242–7.
232. Revol B, Gautier-Veyret E, Arrive C, et al. Pharmacokinetic herb-drug interaction between ginger and crizotinib. *Br J Clin Pharmacol* 2019;86(9):1892–93.
233. Heitmann K, Nordeng H, Holst L. Safety of ginger use in pregnancy: results from a large population-based cohort study. *Eur J Clin Pharmacol* 2013;69(2):269–77.
234. Amieva H, Meillon C, Helmer C, et al. Ginkgo biloba extract and long-term cognitive decline: a 20-year follow-up population-based study. *PLoS ONE* 2013;8(1):e52755.
235. Yuan Q, Wang CW, Shi J, et al. Effects of Ginkgo biloba on dementia: an overview of systematic reviews. *J Ethnopharmacol* 2017;195:1–9.
236. Thancharoen O, Limwattananon C, Waleekhachonloet O, et al. Ginkgo biloba extract (EGb761), cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer's disease: a network meta-analysis. *Drugs Aging* 2019;36(5):435–52.
237. Nicolaï SPA, Kruidenier LM, Bendermacher BLW, et al. Ginkgo biloba for intermittent claudication. *Cochrane Database of Systematic Reviews* 2013, Issue 6.
238. Magalhães PVS, Dean O, Andreazza AC, et al. Antioxidant treatments for schizophrenia. *Cochrane Database of Systematic Reviews* 2016, Issue 2.
239. Zheng W, Xiang YQ, Ng CH, et al. Extract of ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. *Pharmacopsychiatry* 2016;49(3):107–11.
240. Hilton M, Zimmermann E, Hunt W. Ginkgo biloba for tinnitus. *Cochrane Database of Systematic Reviews* 2013, Issue 3.
241. Spiegel R, Kalla R, Mantokoudis G, et al. Ginkgo biloba extract eGb 761® alleviates neurosensory symptoms in patients with dementia: a meta-analysis of treatment effects on tinnitus and dizziness in randomized, placebo-controlled trials. *Clin Interv Aging* 2018;13:1121–27.
242. European Medicines Agency. European Union herbal monograph on Ginkgo biloba L., folium. 2015. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-ginkgo-biloba-l-folium\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-ginkgo-biloba-l-folium_en.pdf)
243. Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardised Ginkgo biloba extract therapy? A systematic review and meta-analysis. *Pharmacotherapy* 2011;31(5):490–502.
244. Hamilton N, Alamri Y, Allan C, et al. Ginkgo biloba-related hyponatraemia: a reminder that herbal supplements are not benign. *Intern Med J* 2019;49(11):1458–60.
245. Stoddard GJ, Archer M, Shane-McWhorter L, et al. Ginkgo and warfarin interaction in a large veterans administration population. *AMIA Annu Symp Proc* 2015;2015:1174–83.
246. Ji H, Zhang G, Yue F. Adverse event due to a likely interaction between sodium aescinate and ginkgo biloba extract: a case report. *J Clin Pharm Ther* 2017;42:237–8.

247. Lai S, Chen J, Kao W. Acute hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency complicated by Ginkgo biloba. *Acta Haematol* 2013;130(4):288–90.
248. Fan L, Mao XQ, Tao GY, et al. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. *Xenobiotica* 2009;39(3):249–54.
249. Sadeghian M, Rahmani S, Zendejdel M, et al. Ginseng and cancer-related fatigue: a systematic review of clinical trials. *Nutr Cancer* 2020; 1–12.
250. An X, Zhang AL, Yang AW, et al. Oral ginseng formulae for stable chronic obstructive pulmonary disease: a systematic review. *Respir Med* 2011;105(2):165–76.
251. Hernández-García D, Granado-Serrano A, Martín-Gari M, et al. Efficacy of Panax ginseng supplementation on blood lipid profile. a meta-analysis and systematic review of clinical randomized trials. *J Ethnopharmacol* 2019;243:112090.
252. Ziaei R, Ghavami A, Ghaedi E, et al. The efficacy of ginseng supplementation on plasma lipid concentration in adults: a systematic review and meta-analysis. *Complement Ther Med* 2020;48:102239.
253. Lee H, Choi J, Lee Y, et al. Ginseng for managing menopausal woman's health: a systematic review of double-blind, randomized, placebo-controlled trials. *Medicine (Baltimore)* 2016;95(38):e4914.
254. Shergis JL, Di YM, Zhang AL, et al. Therapeutic potential of Panax ginseng and ginsenosides in the treatment of chronic obstructive pulmonary disease. *Complement Ther Med* 2014;22(5):944–53.
255. European Medicines Agency. Community herbal monograph on Panax ginseng C.A.Meyer, radix. 2014. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-panax-ginseng-ca-meyer-radix\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-panax-ginseng-ca-meyer-radix_en.pdf)
256. Shergis JL, Zhang AL, Zhou W, et al. Panax ginseng in randomised controlled trials: a systematic review. *Phytother Res* 2013;27(7):949–65.
257. Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. *Drug Saf* 2002;25(5):323–44.
258. Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol* 2004;57(5):592–99.
259. Dasgupta A, Tso G, Wells A. Effect of Asian ginseng, Siberian ginseng, and Indian ayurvedic medicine Ashwagandha on serum digoxin measurement by Digoxin III, a new digoxin immunoassay. *J Clin Lab Anal* 2008;22(4):295–301.
260. Mateo-Carrasco H, Galvez-Contreras MC, Fernandez-Gines FD, et al. Elevated liver enzymes resulting from an interaction between raltegravir and Panax ginseng: a case report and brief review. *Drug Metabol Drug Interact* 2012;27(3):171–5.
261. Koncic MZ, Tomczyk M. New insights into dietary supplements used in sport: active substances, pharmacological and side effects. *Curr Drug Targets* 2013;14(9):1079–92.
262. European Medicines Agency. Community herbal monograph on Eleutherococcus senticosus (Rupr. et Maxim.) Maxim., radix. 2014. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-eleutherococcus-senticosus-rupr-et-maxim-maxim-radix_en.pdf)
263. Hartz AJ, Bentler S, Noyes R, et al. Randomized controlled trial of Siberian ginseng for chronic fatigue. *Psychol Med* 2004;34(1):51–61.
264. Guo S, Liu Y, Lin Z, et al. Effects of eleutheroside B and eleutheroside E on activity of cytochrome P450 in rat liver microsomes. *BMC Complement Altern Med* 2014;14:1.
265. Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? *Arthritis Res Ther* 2012;14(1):1–10.

266. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage* 2014;22(3):363–88.
267. Harrison-Muñoz S, Rojas-Briones V, Irrarrázaval S. Is glucosamine effective for osteoarthritis?. *Medwave* 2017;17(Suppl1):e6867.
268. Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis: from evidence-based medicine to the real-life setting. *Semin Arthritis Rheum* 2016;45(4 Suppl):S3–11.
269. Liu X, Machado G, Eyles J, et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. *Br J Sports Med* 2018;52(3):167–75.
270. Rojas-Briones V, Muñoz SH, Irrarrázaval S. Is chondroitin sulfate effective for osteoarthritis?. *Medwave* 2017;17(Suppl2):e6929.
271. Cerda C, Bruguera M, Pares A. Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease. *World J Gastroenterol* 2013;19(32):5381–84.
272. von Felden J, Montani M, Kessebohm K, et al. Drug-induced acute liver injury mimicking autoimmune hepatitis after intake of dietary supplements containing glucosamine and chondroitin sulfate. *Int J Clin Pharmacol ther* 2013;51(3):219–23.
273. Hoban C, Byard R, Musgrave I. Hypersensitive adverse drug reactions to glucosamine and chondroitin preparations in Australia between 2000 and 2011. *Potsgrad Med J* 2020;96(1134):190–193.
274. UK Medicines Information. Glucosamine: what are the adverse effects?. 2020. At: [www.sps.nhs.uk/wp-content/uploads/2018/05/UKMI\\_QA\\_Glucosamine-adverse-effects\\_update\\_March-2020.pdf](http://www.sps.nhs.uk/wp-content/uploads/2018/05/UKMI_QA_Glucosamine-adverse-effects_update_March-2020.pdf)
275. Knudsen JF, Sokol GH. Potential glucosamine–warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. *Pharmacotherapy* 2008;28(4):540–8.
276. Therapeutic Goods Administration. Australian Adverse Drug Reactions Bulletin, Vol. 27, No. 1, 2008. At: [www.tga.gov.au/publication-issue/australian-adverse-drug-reactions-bulletin-vol-27-no-1](http://www.tga.gov.au/publication-issue/australian-adverse-drug-reactions-bulletin-vol-27-no-1)
277. Tallia AF, Cardone DA. Asthma exacerbation associated with glucosamine–chondroitin supplement. *J Am Board Fam Pract* 2002;15(6):481–4.
278. Esfandiari H, Pakravan M, Zakeri Z, et al. Effect of glucosamine on intraocular pressure: a randomized clinical trial. *Eye (Lond)* 2017;31(3):389–94.
279. Murphy R, Jaccoma E, Rice R, et al. Glucosamine as a possible risk factor for glaucoma. *Invest Ophthalmol Vis Sci* 2009;50(13):5850.
280. Therapeutic Goods Administration. Complementary Medicines Evaluation Committee extracted ratified minutes, 60th meeting, 16 February 2007. At: [www.tga.gov.au/committee-meeting-info/cmec-meeting-60-16-february-2007](http://www.tga.gov.au/committee-meeting-info/cmec-meeting-60-16-february-2007)
281. Dostrovsky NR, Towheed TE, Hudson RW, et al. The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. *Osteoarthritis Cartilage* 2011;19(4):375–80.
282. Biggee B, Blinn C, Nuite M, et al. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. *Ann Rheum Dis* 2007;66(2):260–62.
283. Mandal S, Maji A, Mishra S, et al. Goldenseal (*Hydrastis canadensis* L.) and its active constituents: A critical review of their efficacy and toxicological issues. *Pharmacol Res* 2020;160:105085.

284. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Ther* 2005;77(5):415–26.
285. Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb–drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John ~~wo~~ wort, and Echinacea. *Mol Nutr Food Res* 2008;52(7):755–63.
286. Yamaura K, Shimada M, Nakayama N, et al. Protective effects of goldenseal (*Hydrastis canadensis* L.) on acetaminophen-induced hepatotoxicity through inhibition of CYP2E1 in rats. *Pharmacognosy Res* 2011;3(4).
287. Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. *Metabolism* 2010;59(2):285–92.
288. Gurley BJ, Swain A, Barone GW, et al. Effect of goldenseal (*Hydrastis canadensis*) and kava kava (*Piper methysticum*) supplementation on digoxin pharmacokinetics in humans. *Drug Metab Dispos* 2007;35(2):240–5.
289. Chong NJ, Aziz Z. A systematic review of the efficacy of *Centella asiatica* for improvement of the signs and symptoms of chronic venous insufficiency. *Evid Based Complement Alternat Med* 2013; 2013:627182.
290. Puttarak P, Dilokthornsakul P, Saokaew S, et al. Effects of *centella asiatica* (L.) urb. on cognitive function and mood related outcomes: a systematic review and meta-analysis. *Sci Rep* 2017;7(1):10646.
291. Santos G, Gasca J, Parana R, et al. Profile of herbal and dietary supplements induced liver injury in Latin America: a systematic review of published reports. *Phytother Res* 2020; Epub 2020 Jun 11.
292. Pan Y, Abd-Rashid BA, Ismail Z, et al. In vitro modulatory effects of *Andrographis paniculata*, *Centella asiatica* and *Orthosiphon stamineus* on cytochrome P450 2C19 (CYP2C19). *J Ethnopharmacol* 2011;133(2):881–7.
293. Pan Y, Abd-Rashid BA, Ismail Z, et al. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of *Centella asiatica*. *J Ethnopharmacol* 2010;130(2):275–83.
294. Jorge OA, Jorge AD. Hepatotoxicity associated with the ingestion of *Centella asiatica*. *Rev Esp Enferm Dig* 2005;97(2):115–24.
295. Dantuluri S, P North-lewis, Karthik S. Gotu kola induced hepatotoxicity in a child - need for caution with alternative remedies. *Di Liver Dis* 2011;43(6):500.
296. Nassiri-Asl M, Hosseinzadeh H. Review of the pharmacological effects of *Vitis vinifera* (Grape) and its bioactive compounds. *Phytother Res* 2009;23(9):1197–204.
297. Garavaglia J, Markoski M, Oliveira A, et al. Grape seed oil compounds: biological and chemical actions for health. *Nutr Metab Insights* 2016;9:59–64.
298. Rabe E, Stücker M, Esperester A, et al. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency: results of a double-blind placebo-controlled study. *Eur J Vasc Endovasc Surg* 2011;41(4):540–7.
299. Asbaghi O, Nazarian B, Reiner Z, et al. The effects of grape seed extract on glycemic control, serum lipoproteins, inflammation, and body weight: a systematic review and meta-analysis of randomized controlled trials. *Phytother Res* 2020;34(2):239–253.
300. Anjom-Shoae J, Milajerdi A, Larijani B, et al. Effects of grape seed extract on dyslipidaemia: a systematic review and dose–response meta-analysis of randomised controlled trials. *Br J Nutr* 2020; Epub 2020 Mar 6.

301. European Medicines Agency. European Union herbal monograph on *Vitis vinifera* L., folium. 2017. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitis-vinifera-l-folium-first-version\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitis-vinifera-l-folium-first-version_en.pdf)
302. Ward NC, Hodgson JM, Croft KD, et al. The combination of vitamin C and grape-seed polyphenols increases blood pressure: a randomized, double-blind, placebo-controlled trial. *J Hypertens* 2005;23(2):427–34.
303. Dong SX, Ping ZZ, Xiao WZ, et al. Possible enhancement of the first-pass metabolism of phenacetin by ingestion of grape juice in Chinese subjects. *Br J Clin Pharmacol* 1999;48(4):638–40.
304. Lorenzo J, Munekata P. Phenolic compounds of green tea: health benefits and technological application in food. *Asian Pac J Trop Biomed* 2016;6(8):709–19.
305. Smeriglio A, Barreca D, Bellico E, et al. Proanthocyanidins and hydrolysable tannins: occurrence, dietary intake and pharmacological effects. *Br J Pharmacol* 2016;174(11):1244–62.
306. Filippini T, Malavolti M, Borrelli F, et al. Green tea (*Camellia sinensis*) for the prevention of cancer. *Cochrane Database of Systematic Reviews* 2020, Issue 3.
307. United States Food and Drug Administration. Veregen ointment. 2006. At: [www.accessdata.fda.gov/drugsatfda\\_docs/nda/2006/021902s000TOC.cfm](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000TOC.cfm)
308. Jurgens T, Whelan A, Killian L, et al. Green tea for weight loss and weight maintenance in overweight or obese adults. *Cochrane Database of Systematic Reviews* 2012, Issue 12.
309. Therapeutic Goods Administration. *Camellia sinensis* (green tea) extract: safety advisory—potential risk of harm to the liver. 2018. At: [www.tga.gov.au/alert/camellia-sinensis-green-tea-extract](http://www.tga.gov.au/alert/camellia-sinensis-green-tea-extract)
310. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. *Ann Pharmacother* 1999;33(4):426–8.
311. Nutescu E, Shapiro N, Ibrahim S, et al. Warfarin and its interactions with foods, herbs and other dietary supplements. *Expert Opin Drug Saf* 2006;5(3):433–451.
312. Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. *Blood* 2009;113(23):5927–37.
313. Werba J, Misaka S, Giroli M, et al. Update of green tea interactions with cardiovascular drugs and putative mechanisms. *J Food Drug Anal* 2018;26(2S):S72–7.
314. Roth M, Timmerman BN, Hagenbuch B. Interactions of green tea catechins with organic anion-transporting polypeptides. *Drug Metab Dispos* 2011;39(5):920–6.
315. Misaka S, Yatabe J, Muller F, et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. *Clin Pharmacol Ther* 2014;95(4):432–8.
316. Chung JH, Choi DH, Choi JS. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. *Biopharm Drug Dispos* 2009;30(2):90–3.
317. McLellan TM, Caldwell JA, Liebermann HR. A review of caffeine's effects on cognitive, physical and occupational performance. *Neurosci Biobehav Rev* 2016;71:294–312.
318. Harpaz E, Tamir S, Weinstein A, et al. The effect of caffeine on energy balance. *J Basic Clin Physiol Pharmacol* 2017;28(1):1–10.
319. Gavrieli A, Karfopoulou E, Kardatou E, et al. Effect of different amounts of coffee on dietary intake and appetite of normal-weight and overweight/obese individuals. *Obesity (Silver Spring)* 2013;21(6):1127–32.

320. Rodrigues C, del Giglio A. Paullinia cupana (guarana) for chemotherapy-induced fatigue in patients with solid tumors: a meta-analysis. *Clin Onc Let* 2018;3(1–2):53–61.
321. Konstantinos F, Heun R. The effects of guarana (Paullinia cupana) supplementation on the cognitive performance of young healthy adults: a systematic review. *Glob Psychiatry* 2019;2(2):171–82.
322. Pennay A, Lubman D, Miller P. Combining energy drinks and alcohol: a recipe for trouble? *Aust Fam Physician* 2011;40(3):104–7.
323. Lalanne L, Lutz PE, Paille F. Acute impact of caffeinated alcoholic beverages on cognition: a systematic review. *Prog Neuropsychopharmacol Biol Psychiatry* 2017;76:188–94.
324. Vaz J, Kulkarni C, David J, et al. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers. *Indian J Exp Biol* 1998;36(1):112–14.
325. Shet M, McPhaul M, Fisher C, et al. Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. *Drug Metab Dispos* 1997;25(11):1298–303.
326. Hoeven NVD, Visser I, Schene A, et al. Severe hypertension related to caffeinated coffee and tranlycypromine: a case report. *Ann Intern Med* 2014;160(9):657–8.
327. Lee DR, Lee J, Rota M, et al. Coffee consumption and risk of fractures: a systematic review and dose-response meta-analysis. *Bone* 2014;63:20–8.
328. Wikoff D, Welsh BT, Henderson R, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. *Food Chem Toxicol* 2017;Epub 2017 Feb 24.
329. Bryant C, Dowell C, Fairbrother G. Caffeine reduction education to improve urinary symptoms. *Br J Nurs* 2002;11(8):560–565.
330. Jahanfar S, Jaafar SH. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes. *Cochrane Database of Systematic Reviews* 2015, Issue 6.
331. Morgan S, Koren G, Bozzo P. Is caffeine consumption safe during pregnancy?. 2013;59(4):361–2.
332. Australian Beverages Council. What's the go with energy drinks?. 2020. At: [www.australianbeverages.org/energy-drinks-microsite/](http://www.australianbeverages.org/energy-drinks-microsite/)
333. Food Standards Australian New Zealand. Caffeine. 2019. At: [www.foodstandards.gov.au/consumer/generalissues/Pages/Caffeine.aspx](http://www.foodstandards.gov.au/consumer/generalissues/Pages/Caffeine.aspx)
334. Seifert SM, Schaechter JL, Hershoren ER, et al. Health effects of energy drinks on children, adolescents, and young adults. *Pediatrics* 2011;127(3):511–28.
335. Ruxton C. The suitability of caffeinated drinks for children: a systematic review of randomised controlled trials, observational studies and expert panel guidelines. *J Hum Nutr Diet* 2014;27:342–57.
336. Guo R, Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure. *Cochrane Database of Systematic Reviews* 2008, Issue 1.
337. Holubarsch CJF, Colucci WS, Meinertz T, et al. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. *Eur J Heart Fail* 2008;10(12):1255–63.
338. Zick SM, Gillespie B, Aaronson KD. The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. *Eur J Heart Fail* 2008;10(6):587–93.
339. Holubarsch C, Colucci W, Eha J. Benefit–risk assessment of Crataegus extract WS 1442: an evidence-based review. *Am J Cardiovasc Drugs* 2018;18(1):25–36.

340. Rogers K, Grice I, Griffiths L. Inhibition of platelet aggregation and 5-HT release by extracts of Australian plants used traditionally as headache treatments. *Eur J Pharm Sci* 2000;9(4):355–63.
341. Tankanow R, Tamer HR, Streetman DS, et al. Interaction study between digoxin and a preparation of hawthorn (*Crataegus oxyacantha*). *J Clin Pharmacol* 2003;43(6):637–42.
342. Dasgupta A, Kidd L, Poindexter BJ, et al. Interference of hawthorn on serum digoxin measurements by immunoassays and pharmacodynamic interaction with digoxin. *Arch Pathol Lab Med* 2010;134(8):1188–92.
343. Holzinger F, Chenot JF. Systematic review of clinical trials assessing the effectiveness of ivy leaf (*Hedera helix*) for acute upper respiratory tract infections. *Evid Based Complement Alternat Med* 2011;2011:382789.
344. Schaefer A, Kehr M, Giannetti B, et al. A randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract (EA 575<sup>®</sup>) vs. placebo in the treatment of adults with acute cough. *Pharmazie* 2016;71(9):504–9.
345. Kardos P, Dinh Q, Fuchs K, et al. German Respiratory Society guidelines for diagnosis and treatment of adults suffering from acute, subacute and chronic cough. *Respir Med* 2020;170:105939.
346. European Medicines Agency. European Union herbal monograph on *Hedera helix* L., folium. 2017. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-hedera-helix-l-folium-revision-2\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-hedera-helix-l-folium-revision-2_en.pdf)
347. Fazio S, Pouso J, Dolinsky D, et al. Tolerance, safety and efficacy of *Hedera helix* extract in inflammatory bronchial diseases under clinical practice conditions: a prospective, open, multicentre postmarketing study in 9657 patients. *Phytomedicine* 2009;16(1):17–24.
348. Rehman S, Kim I, Choi M, et al. Time-dependent inhibition of CYP2C8 and CYP2C19 by *Hedera helix* extracts, a traditional respiratory herbal medicine. *Molecules* 2017;22(7):1241.
349. Lang C, Röttger-Lüer P, Staiger C. A valuable option for the treatment of respiratory diseases: review on the clinical evidence of the ivy leaves dry extract EA 575<sup>®</sup>. *Planta Med* 2015;81(12–13):968–74.
350. Sarris J, Moylan S, Camfield DA, et al. Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: a review of current evidence. *Evid Based Complement Alternat Med* 2012;2012:809653.
351. Sarris J, Stough C, Bousman C, et al. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. *J Clin Psychopharmacol* 2013;33(5):643–8.
352. Sarris J, Stough C, Teschke R, et al. Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. *Phytother Res* 2013;27(11):1723–8.
353. European Medicines Agency. Assessment report on *Piper methysticum* G. Forst., rhizoma. 2017. At: [www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-piper-methysticum-g-forst-rhizoma\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-piper-methysticum-g-forst-rhizoma_en.pdf)
354. Therapeutic Goods Administration. The Poison Standard (the SUSMP). 2020. At: [www.tga.gov.au/publication/poisons-standard-susmp](http://www.tga.gov.au/publication/poisons-standard-susmp)
355. Food Standards Australia New Zealand. Kava: a human health risk assessment. Technical report series no. 30. Canberra: FSANZ; 2005. At: [www.foodstandards.gov.au/publications/documents/30\\_Kava1.pdf](http://www.foodstandards.gov.au/publications/documents/30_Kava1.pdf)
356. Wainigolo I, Kool B, Nosa V, et al. Is driving under the influence of kava associated with motor vehicle crashes? A systematic review of the epidemiological literature. *Aust N Z J Public Health* 2015;39(5):495–9.

357. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. *Cochrane Database of Systematic Reviews* 2003, Issue 1.
358. Teschke R, Sarris J, Schweitzer I. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. *Br J Clin Pharmacol* 2011;73(2):170–4.
359. European Medicines Agency. Assessment report on *Fucus vesiculosus* L., thallus. 2014. At: [www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-fucus-vesiculosus-l-thallus\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-fucus-vesiculosus-l-thallus_en.pdf)
360. Leung AM, Braverman LE. Iodine-induced thyroid dysfunction. *Curr Opin Endocrinol Diabetes Obes* 2012;19(5):414–9.
361. Mathew L, Burney M, Gaikwad A, et al. Preclinical evaluation of safety of fucoidan extracts From *Undaria pinnatifida* and *Fucus vesiculosus* for use in cancer treatment. *Integr Cancer Ther* 2017;16(4):572–584.
362. Spinks EA, Fenwick GR. The determination of glycyrrhizin in selected UK liquorice products. *Food Addit Contam* 1990;7(6):769–78.
363. Strandberg TE, Andersson S, Järvenpää AL, et al. Preterm birth and licorice consumption during pregnancy. *Am J Epidemiol* 2002;156(9):803–5.
364. Griffith R, DeLong D, Nelson J. Relation of arginine–lysine antagonism to herpes simplex growth in tissue culture. *Chemotherapy* 1981;27(3):209–13.
365. Chi CC, Wang SH, Delamere FM, et al. Interventions for prevention of herpes simplex labialis (cold sores on the lips). *Cochrane Database of Systematic Reviews* 2015, Issue 8.
366. Lo JC, Chertow GM, Rennke H, et al. Fanconi’s syndrome and tubulointerstitial nephritis in association with L-lysine ingestion. *Am J Kidney Dis* 1996;28(4):614–17.
367. Civitelli R, Villareal DT, Agnusdei D, et al. Dietary L-lysine and calcium metabolism in humans. *Nutrition* 1992;8(6):400–5.
368. Voroneanu L, Nistor I, Dumea R, et al. Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. *J Diabetes Res* 2016;2016:5147468.
369. de-Avelar CR, Pereira EM, Costa PRDF, et al. Effect of silymarin on biochemical indicators in patients with liver disease: systematic review with meta-analysis. *World J Gastroenterol* 2017;23(27):5004–17.
370. Gurley B, Hubbard MA, Williams DK, et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. *J Clin Pharmacol* 2006;46(2):201–13.
371. Kawaguchi-Suzuki M, Frye R, Zhu H. The effects of milk thistle (*Silybum marianum*) on human cytochrome P450 activity. *Drug Metab Dispos* 2014;42(10):1611–16.
372. Jiao Z, Shi X, Li Z, et al. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. *Br J Clin Pharmacol* 2009;68(1):47–60.
373. Lockyer S, Rowland I, Spencer JP, et al. Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trial. *Eur J Nutr* 2016; Epub 2016 Mar 7.
374. Widmer R, Flammer A, Lermann L, et al. The Mediterranean diet, its components, and cardiovascular disease. *Am J Med* 2015;128(3):229–38.
375. Susalit E, Agus N, Effendi I, et al. Olive (*Olea europaea*) leaf extract effective in patients with stage-1 hypertension: comparison with captopril. *Phytomedicine* 2011;18(4):251–8.

376. Timmer A, Günther J, Motschall E, et al. Pelargonium sidoides extract for treating acute respiratory tract infections. *Cochrane Database of Systematic Reviews* 2013, Issue 10.
377. Wagner L, Cramer H, Klose P, et al. Herbal medicine for cough: a systematic review and meta-analysis. *Forsch Komplementmed* 2015;22(6):359–68.
378. Careddu D, Pettenazzo A. Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children. *Int J Gen Med* 2018;11:91–98.
379. Blackmores Institute. Pelargonium (Pelargonium sidoides). At: [www.blackmoresinstitute.org](http://www.blackmoresinstitute.org)
380. Hawrelak J, Wohlmuth H, Pattinson M, et al. Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. *Complement Ther Med* 2020;48:102233.
381. European Medicines Agency. European Union herbal monograph on Mentha x piperita L., aetheroleum. 2020. At: [www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-mentha-x-piperita-l-aetheroleum-revision-1\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/european-union-herbal-monograph-mentha-x-piperita-l-aetheroleum-revision-1_en.pdf)
382. Therapeutic Goods Administration. ARGOM Appendix 5: Guidelines on OTC applications for specific substances. 2012. At: [www.tga.gov.au/publication/argom-appendix-5-guidelines-otc-applications-specific-substances](http://www.tga.gov.au/publication/argom-appendix-5-guidelines-otc-applications-specific-substances)
383. Wachter VJ, Wong S, Wong HT. Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. *J Pharm Sci* 2002;91(1):77–90.
384. Guarner F, Sanders ME, Eliakim R, et al. World Gastroenterology Organisation global guidelines: probiotics and prebiotics. 2017. At: [www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics](http://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics)
385. Su G, Ko C, Bercik P, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. *Gastroenterology* 2020;159:697–705.
386. McFarland L, Evans C, Goldstein E. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. *Front Med (Lausanne)* 2018;5:124.
387. Newlove-Delgado TV, Martin AE, Abbott RA, et al. Dietary interventions for recurrent abdominal pain in childhood. *Cochrane Database of Systematic Reviews* 2017, Issue 3.
388. Vandenplas Y. Probiotics and prebiotics in infectious gastroenteritis. *Best Pract Res Clin Gastroenterol* 2016;30(1):49–53.
389. Li Y-T, Xu H, Ye J-Z, et al. Efficacy of Lactobacillus rhamnosus GG in treatment of acute pediatric diarrhea: a systematic review with meta-analysis. *World J Gastroenterol* 2019;25(33):4999–5016.
390. Patro-Golab B, Szajewska H. Systematic review with meta-analysis: Lactobacillus reuteri DSM 17938 for treating acute gastroenteritis in children—an update. *Nutrients* 2019;11(11):2762.
391. Szajewska H, Kolodziej M, Gieruszczak-Bialek D, et al. Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children—a 2019 update. *Aliment Pharmacol Ther* 2019;49(11):1376–84.
392. Szajewska H, Kolodziej M, Zalewski B. Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update. *Aliment Pharmacol Ther* 2020;51(7):678–88.
393. Yang B, Lu P, Li M, et al. A meta-analysis of the effects of probiotics and synbiotics in children with acute diarrhea. *Medicine* 2019;98(37):e16618.
394. McFarland L, Goh S. Are probiotics and prebiotics effective in the prevention of travellers' diarrhea: a systematic review and meta-analysis. *Travel Med Infect Dis* 2018;27:11–19.

395. Fiocchi A, Pawankar R, Cuello-Garcia C, et al. World Allergy Organization—McMaster University guidelines for allergic disease prevention (GLAD-P): probiotics. *World Allergy Organ J* 2015;8(1):4.
396. Amalia N, Orchard D, Francis K, et al. Systematic review and meta-analysis on the use of probiotic supplementation in pregnant mother, breastfeeding mother and infant for the prevention of atopic dermatitis in children. *Australas J Dermatol* 2019;61(2):e158–73.
397. Makrgeorgou A, Leonardi-Bee J, Bath-Hextall F, et al. Probiotics for treating eczema. *Cochrane Database of Systematic Reviews* 2018, Issue 11.
398. Tan-Lim C, Esteban-Ipac N, Mantaring J, et al. Comparative effectiveness of probiotic strains for the treatment of pediatric atopic dermatitis: a systematic review and network meta-analysis. *Pediatr Allergy Immunol* 2020; Epub 2020 Jun 10.
399. Rondanelli M, Faliva MA, Perna S, et al. Using probiotics in clinical practice: where are we now? A review of existing meta-analyses. *Gut Microbes* 2017;Epub 2017 Jun 22.
400. Guvenc IA, Muluk NB, Mutlu FS, et al. Do probiotics have a role in the treatment of allergic rhinitis? A comprehensive systematic review and meta analysis. *Am J Rhinol Allergy* 2016;Epub 2016 Jul 20.
401. Hsiao K, Ponsonby A, Axelrad C, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. *Lancet Child Adolesc Health* 2017;Epub 2017 Aug 15.
402. Tan-Lim C, Esteban-Ipac N. Probiotics as treatment for food allergies among pediatric patients: a meta-analysis. *World Allergy Organ J* 2018;11:25.
403. S Campos dos Santos, Konstanyner T, Cocco R. Effects of probiotics in the treatment of food hypersensitivity in children: a systematic review. *Allergol Immunopathol (Madr)* 2020;48(1):95–104.
404. Goldenberg J, Yap C, Lytvyn L, et al. Probiotics for the prevention of *Clostridium difficile*–associated diarrhea in adults and children. *Cochrane Database of Systematic Reviews* 2017, Issue 12.
405. Szajewska H, Canani RB, Guarino A, et al. Probiotics for the prevention of antibiotic-associated diarrhea in children. *J Pediatr Gastroenterol Nutr* 2016;62(3):495–506.
406. Guo Q, Goldenberg J, Humphrey C, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. *Cochrane Database of Systematic Reviews* 2019, Issue 4.
407. Derwa Y, Gracie DJ, Hamlin PJ, et al. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. *Aliment Pharmacol Ther* 2017;46(4):389–400.
408. Limketkai B, Akobeng A, Gordon M, et al. Probiotics for induction of remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2020, Issue 7.
409. Coffey M, Garg M, Homaira N, et al. Probiotics for people with cystic fibrosis. *Cochrane Database of Systematic Reviews* 2020, Issue 1.
410. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. *Cochrane Database of Systematic Reviews* 2015, Issue 12.
411. Xie H, Feng D, Wei D, et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. *Cochrane Database of Systematic Reviews* 2017, Issue 11.
412. Wang Z, He Y, Zheng Y. Probiotics for the treatment of bacterial vaginosis: a meta-analysis. *Int J Environ Res Public Health* 2019;16(20):3859.
413. Dryl R, Szajewska H. Probiotics for management of infantile colic: a systematic review of randomized controlled trials. *Arch Med Sci* 2018;14(5):1137-43.

414. Sung V, Amico FD, Cabana M, et al. Lactobacillus reuteri to treat infant colic: a meta-analysis. *Paediatrics* 2018;141(1):e20171811.
415. Ong T, Gordon M, Banks S, et al. Probiotics to prevent infantile colic. *Cochrane Database of Systematic Reviews* 2019, Issue 3.
416. Ellwood J, Draper-Rodi J, Carnes D. Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines. *BMJ Open* 2020;10(2):e035405.
417. Braegger C, Chmielewska A, Decsi T, et al. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. *J Pediatr Gastroenterol Nutr* 2011;52(2):238–50.
418. Martin CR, Ling P, Blackburn GL. Review of infant feeding: key features of breast milk and infant formula. *Nutrients* 2016;8(5):279.
419. National Health and Medical Research Council. *Infant feeding guidelines: information for health workers*. Canberra: NHMRC; 2012. At: [www.nhmrc.gov.au/guidelines-publications/n56](http://www.nhmrc.gov.au/guidelines-publications/n56)
420. Kaur L, Gordon M, Baines P, et al. Probiotics for induction of remission in ulcerative colitis. *Cochrane Database of Systematic Reviews* 2020, Issue 3.
421. Iheozor-Ejiofor Z, Kaur L, Gordon M, et al. Probiotics for maintenance of remission in ulcerative colitis. *Cochrane Database of Systematic Reviews* 2020, Issue 3.
422. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. *Cochrane Database of Systematic Reviews* 2015, Issue 2.
423. Crovesy L, Ostrowski M, Ferreira DMTP, et al. Effect of Lactobacillus on body weight and body fat in overweight subjects: a systematic review of randomized controlled clinical trials. *Int J Obes (Lond)* 2017;Epub 2017 Jul 10.
424. Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. *BMJ Open* 2019;9:e017995.
425. Hungin APS, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice—an evidence-based international guide. *Aliment Pharmacol Ther* 2013;38(8):864–86.
426. Hojsak I, Fabiano V, Pop T, et al. Guidance on the use of probiotics in clinical practice in children with selected clinical conditions and in specific vulnerable groups. *Acta Paediatrica* 2018;107(6):927–937.
427. Roy U, Jessani L, Rudramurthy S, et al. Seven cases of *Saccharomyces* fungaemia related to use of probiotics. *Mycoses* 2017;60(6):375–80.
428. Meini S, laureano R, Fani L, et al. Breakthrough *Lactobacillus rhamnosus* GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature. *Infection* 2015;43(6):777–81.
429. Groote MD, Frank D, Dowell E, et al. *Lactobacillus rhamnosus* GG bacteremia associated with probiotic use in a child with short gut syndrome. *Pediatr Infect Dis J* 2005;24:278–80.
430. Sato S, Uchida T, Kuwana S, et al. Bacteremia induced by *Bifidobacterium breve* in a newborn with cloacal exstrophy. *Paediatr Int* 2016;58(11):1226–8.
431. Sanders ME, Merenstein DJ, Ouwehand AC, et al. Probiotic use in at-risk populations. *J Am Pharm Assoc* 2016;56(6):680–6.
432. Aaron J, Sobieszczyk M, Weiner S, et al. *Lactobacillus rhamnosus* endocarditis after upper endoscopy. *Open Forum Infect Dis* 2017;4(2):ofx085.

433. Franko B, Vaillant M, Recule C, et al. Lactobacillus paracasei endocarditis in a consumer of probiotics. *Med Mal Infect* 2013;43(4):171–3.
434. Kato K, Funabashi N, Takaoka H, et al. Lactobacillus paracasei endocarditis in a consumer of probiotics with advanced and severe bicuspid aortic valve stenosis complicated with diffuse left ventricular mid-layer fibrosis. *Int J Cardiol* 2016;224:157–61.
435. Elias J, Bozzo P, Einarson A. Are probiotics safe for use during pregnancy and lactation?. *Can Fam Physician* 2011;57(3):299–301.
436. Royal Australian College of General Practitioners. Probiotics in pregnancy for infant atopic eczema. Melbourne: RACGP; 2016. At: [www.racgp.org.au/your-practice/guidelines/handi/interventions/children/probiotics-in-pregnancy-for-infant-atopic-eczema](http://www.racgp.org.au/your-practice/guidelines/handi/interventions/children/probiotics-in-pregnancy-for-infant-atopic-eczema)
437. Jarde A, Lewis-Mikhael A, Moayyedi P, et al. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. *BMC Pregnancy Childbirth* 2018;18:14.
438. North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of the North American Menopause Society. *Menopause* 2015;22(11):1155–72.
439. Myers SP, Vigar V. Effects of a standardised extract of *Trifolium pratense* (Promensil) at a dosage of 80mg in the treatment of menopausal hot flushes: a systematic review and meta-analysis. *Phytomedicine* 2017;24:141–7.
440. Lagari VS, Levis S. Phytoestrogens for menopausal bone loss and climacteric symptoms. *J Steroid Biochem Mol Biol* 2014;139:294–301.
441. Abdi F, Alimoradi Z, Haqi P, et al. Effects of phytoestrogens on bone mineral density during the menopause transition: a systematic review of randomized, controlled trials. *Climacteric* 2016;19(6):535–45.
442. Lambert MNT, Hu LM, Jeppesen PB. A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women. *Am J Clin Nutr* 2017;106(3):801–11.
443. Sansai K, Takuathung M, Khatsri R, et al. Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. *Osteoporos Int* 2020;31(10):1853–64.
444. Schmidt M, Arjomand-Wolkart K, Birkhauser MH, et al. Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints. *Gynecol Endocrinol* 2016;32(6):427–30.
445. Chen L, Ko N, Chen K. Isoflavone supplements for menopausal women: a systematic review. *Nutrients* 2019;11(11):2649.
446. Orr A, Parker R. Red clover causing symptoms suggestive of methotrexate toxicity in a patient on high-dose methotrexate. *Menopause Int* 2013;19(3):133–4.
447. Hasan Y, Schoenherr D, Martinez AA, et al. Prostate-specific natural health products (dietary supplements) radiosensitize normal prostate cells. *Int J Radiat Oncol Biol Phys* 2010;76(3):896–904.
448. Galizia I, Oldani L, Macritchie K, et al. S-adenosyl methionine (SAME) for depression in adults. *Cochrane Database of Systematic Reviews* 2016, Issue 10.
449. Guo T, Chang L, Xiao Y, et al. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. *PLoS ONE* 2015;10(3):e0122124.

450. Nouredin M, Sander-Struckmeier S, Mato J. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: a systematic review. *World J Hepatol* 2020;12(2):46–63.
451. Mahli G, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust N Z J Psychiatry* 2015;49(12):1–185.
452. Sharma A, Gerbarg P, Bottiglieri T, et al. S-adenosylmethionine (SAME) for neuropsychiatric disorders: a clinician-oriented review of research. *J Clin Psychiatry* 2017;78(6):e656–67.
453. Rutjes AWS, Nüesch E, Reichenbach S, et al. S-adenosylmethionine for osteoarthritis of the knee or hip. *Cochrane Database of Systematic Reviews* 2009, Issue 4.
454. de-Silva V, El-metwally A, Ernst E, et al. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. *Rheumatology (Oxford)* 2011;50(5):911–20.
455. European Medicines Agency. European Union herbal monograph on *Serenoa repens* (W. Bartram) Small, fructus. 2015. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-serenoa-repens-w-bartram-small-fructus\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-serenoa-repens-w-bartram-small-fructus_en.pdf)
456. Tacklind J, MacDonald R, Rutks I, et al. *Serenoa repens* for benign prostatic hyperplasia. *Cochrane Database of Systematic Reviews* 2012, Issue 12.
457. Vela-Navarrete R, Alcaraz A, Rodriguez-Antolin A, et al. Efficacy and safety of a hexanic extract of *Serenoa repens* for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials and observational studies. *BJU International* 2018;122:1049–66.
458. Russo G, Scandura C, Mauro M, et al. Clinical efficacy of *Serenoa repens* versus placebo versus alpha-blockers for the treatment of lower urinary tract symptoms/benign prostatic enlargement: a systematic review and network meta-analysis of randomized placebo-controlled clinical trials. *Eur Urol Focus* 2020;S2405–4569(20):30018–3.
459. Anceschi R, Bisi M, Ghidini N, et al. *Serenoa repens* (Permixon®) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia. *Minerva Urol Nefrol* 2010;62(3):219–23.
460. Neff KD, Sandoval HP, Castro LEFD, et al. Factors associated with intraoperative floppy iris syndrome. *Ophthalmology* 2009;116(4):658–63.
461. Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of saw palmetto herb: a case report and review of literature. *J Intern Med* 2001;250(2):167–9.
462. European Medicines Agency. Assessment report on *Glycine max*(L.) Merr., semen. 2018. At: [www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-glycine-max-l-merr-semen-first-version\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-glycine-max-l-merr-semen-first-version_en.pdf)
463. Rietjens IMCM, Lousse J, Beekmann K. The potential health effects of dietary phytoestrogens. *Br J Pharmacol* 2017;174(11):1263–80.
464. Cui C, Birru R, Snitz B, et al. Effects of soy isoflavones on cognitive function: a systematic review and meta-analysis of randomized controlled trials. *Nutr Rev* 2020;78(2):134–44.
465. Qin Y, Niu K, Zeng Y, et al. Isoflavones for hypercholesterolaemia in adults. *Cochrane Database of Systematic Reviews* 2013, Issue 6.
466. Tokede OA, Onabanjo TA, Yansane A, et al. Soya products and serum lipids: a meta-analysis of randomised controlled trials. *Br J Nutr* 2015;114(6):831–43.

467. Moradi M, Daneshzad E, Azadbakht L. The effects of isolated soy protein, isolated soy isoflavones and soy protein containing isoflavones on serum lipids in postmenopausal women: a systematic review and meta-analysis. *Crit Rev Food Sci Nutr* 2019;Epub 2019 Dec 20.
468. Vandenplas Y. Prevention and management of cow's milk allergy in non-exclusively breastfed infants. *Nutrients* 2017;9(7):E731.
469. Vandenplas Y, Castrellon PG, Rivas R, et al. Safety of soya-based infant formulas in children. *Br J Nutr* 2014;111(8):1340–60.
470. Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. *Cochrane Database of Systematic Reviews* 2013, Issue 12.
471. Kerstetter JE, Wall DE, O'Brien KO, et al. Meat and soy protein affect calcium homeostasis in healthy women. *J Nutr* 2006;136(7):1890–5.
472. National Health and Medical Research Council. *Infant feeding guidelines*. Canberra: NHMRC; 2012.
473. Peng WX, Li HD, Zhou HH. Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. *Eur J Clin Pharmacol* 2003;59(3):237–41.
474. Serban MC, Sahebkar A, Dragan S, et al. A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations. *Clin Nutr* 2016;35(4):842–51.
475. Huang H, Liao D, PU R, et al. Quantifying the effects of spirulina supplementation on plasma lipid and glucose concentrations, body weight, and blood pressure. *Diabetes Metab Syndr Obes* 2018;11:729–42.
476. Hamedifard Z, Milajerdi A, Reiner Z, et al. The effects of spirulina on glycemic control and serum lipoproteins in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. *Phytother Res* 2019;33(10):2609–21.
477. Moradi S, Ziaei R, Foshati S, et al. Effects of spirulina supplementation on obesity: a systematic review and meta-analysis of randomized clinical trials. *Complement Ther Med* 2019;47:102211.
478. Zarezadeh M, Faghfour A, Radkhah N, et al. Spirulina supplementation and anthropometric indices: a systematic review and meta-analysis of controlled clinical trials. *Phytother Res* 2020;Epub 2020 Sep 23.
479. Iwasa M, Yamamoto M, Tanaka Y, et al. Spirulina-associated hepatotoxicity. *Am J Gastroenterol* 2002;97(12):3212–13.
480. Savranoglu S, Turner TB. Inhibitory effects of spirulina platensis on carcinogen-activating cytochrome P450 isozymes and potential for drug interactions. *Int J Toxicol* 2013;32(5):376–84.
481. Suliburska J, Szulinska M, Tinkov A, et al. Effect of Spirulina maxima supplementation on calcium, magnesium, iron, and zinc status in obese patients with treated hypertension. *Biol Trace Elem Res* 2016;173(1):1–6.
482. Therapeutic Goods Administration. *Compositional guideline: Arthrospira platensis*. 2011. At: [www.tga.gov.au/compositional-guideline/arthrospira-platensis](http://www.tga.gov.au/compositional-guideline/arthrospira-platensis)
483. Linde K, Berner MM, Kriston L. St John's wort for major depression. *Cochrane Database of Systematic Reviews* 2008, Issue 4.
484. Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John's wort for major depressive disorder. *Syst Rev* 2016;5(1):148.
485. Ng QX, Venkatanarayanan N, Ho CY. Clinical use of Hypericum perforatum (St John's wort) in depression: a meta-analysis. *J Affect Disord* 2017;210:211–21.

486. Liu YR, Jiang YL, Huang RQ, et al. Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety. *Climacteric* 2014;17(4):325–35.
487. European Medicines Agency. Community herbal monograph on Hypericum perforatum L., herba. 2009. At: [www.ema.europa.eu/en/medicines](http://www.ema.europa.eu/en/medicines)
488. Hoban CL, Byard RW, Musgrave IF. A comparison of patterns of spontaneous adverse drug reaction reporting with St. John's Wort and fluoxetine during the period 2000–2013. *Clin Exp Pharmacol Physiol* 2015;42(7):747–51.
489. Ferrara M, Mungai F, Starace F. St John's wort (Hypericum perforatum)-induced psychosis: a case report. *J Med Case Rep* 2017;11:137.
490. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St John's Wort. *Lancet* 1998;352(9134):1121–2.
491. Imai H, Kotegawa T, Tsutsumi K, et al. The recovery time-course of CYP3A after induction by St John's wort administration. *Br J Clin Pharmacol* 2008;65(5):701–7.
492. Bauer S, Stormer E, Johne A, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. *Br J Clin Pharmacol* 2003;55(2):203–11.
493. Medicines and Healthcare Products Regulatory Agency. Herbal ingredient St John's wort may interact with all antiepileptics. *MHRA Drug Safety Update* 2007;1(4):7.
494. Therapeutic Goods Administration. St John's Wort: information sheet for health care professionals. 2000. At: [www.tga.gov.au/alert/st-johns-wort-information-sheet-health-care-professionals](http://www.tga.gov.au/alert/st-johns-wort-information-sheet-health-care-professionals)
495. Dolton MJ, Mikus G, Weiss J, et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. *J Antimicrob Chemother* 2014;69(6):1633–41.
496. Faculty of Sexual and Reproductive Healthcare. Clinical guidance: drug interactions with hormonal contraception. London: FSRH; 2017.
497. Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. *J Clin Pharmacol* 2006;46(11):1370–8.
498. Hojo Y, Echizenya M, Ohkubo T, et al. Drug interaction between St John's wort and zolpidem in healthy subjects. *J Clin Pharm Ther* 2011;36(6):711–5.
499. Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular). *J Nat Prod* 2010;73(5):1015–21.
500. Cao H, Yang G, Wang Y, et al. Complementary therapies for acne vulgaris. *Cochrane Database of Systematic Reviews* 2015, Issue 1.
501. Savla K, Le J, Pucker A. Tea tree oil for Demodex blepharitis. *Cochrane Database of Systematic Reviews* 2020, Issue 6.
502. Barker SC, Altman PM. A randomised, assessor blind, parallel group comparative efficacy trial of three products for the treatment of head lice in children: melaleuca oil and lavender oil, pyrethrins and piperonyl butoxide, and a 'suffocation' product. *BMC Dermatol* 2010;10(6).
503. Barker SC, Altman PM. An ex vivo, assessor blind, randomised, parallel group, comparative efficacy trial of the ovicidal activity of three pediculicides after a single application: melaleuca oil and lavender oil, eucalyptus oil and lemon tea tree oil, and a 'suffocation' pediculicide. *BMC Dermatol* 2011;11:14.
504. Buck DS, Nidorf DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. *J Fam Pract* 1994;38(6):601–5.

505. Martin KW, Ernst E. Herbal medicines for treatment of fungal infections: a systematic review of controlled clinical trials. *Mycoses* 2004;47(3–4):87–92.
506. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. *Cochrane Database of Systematic Reviews* 2007, Issue 3.
507. Rogerson S, Riches CJ, Jennings C, et al. The effect of five weeks of *Tribulus terrestris* supplementation on muscle strength and body composition during preseason training in elite rugby league players. *J Strength Cond Res* 2007;21(2):348–53.
508. Sanagoo S, Oskouei B, Abdollahi N, et al. Effect of *Tribulus terrestris* L. on sperm parameters in men with idiopathic infertility: A systematic review. *Complement Ther Med* 2019;42:95–103.
509. Qureshi A, Naughton DP, Petroczi A. A systematic review on the herbal extract *Tribulus terrestris* and the roots of its putative aphrodisiac and performance enhancing effect. *J Diet Suppl* 2014;11(1):64–79.
510. Gama CR, Lasmar R, Gama GF, et al. Clinical assessment of *Tribulus terrestris* extract in the treatment of female sexual dysfunction. *Clin Med Insights Womens Health* 2014;7:45–50.
511. Talasaz AH, Abbasi MR, Abkhiz S, et al. *Tribulus terrestris*–induced severe nephrotoxicity in a young healthy male. *Nephrol Dial Transplant* 2010;25(11):3792–3.
512. Ryan M, Iazar I, Nadasdy GM, et al. Acute kidney injury and hyperbilirubinemia in a young male after ingestion of *Tribulus terrestris*. *Clin Nephrol* 2015;83(3):177–83.
513. Ivanova A, Serly J, Dinchev D, et al. Screening of some saponins and phenolic components of *Tribulus terrestris* and *Smilax excelsa* as MDR modulators. *In Vivo* 2009;23(4):545–50.
514. Sahebkar A, Henrotin Y. Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials. *Pain Med* 2016;17(6):1192–202.
515. Tabrizi R, Vakili S, Akbari M, et al. The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. *Phytother Res* 2019;33(2):253–62.
516. White CM, Pasupuleti V, Roman Y, et al. Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. *Pharmacol Res* 2019;146:104280.
517. Fernandez-Lazaro D, Mielgo-Ayuso J, Calvo J, et al. Modulation of exercise-induced muscle damage, inflammation, and oxidative markers by curcumin supplementation in a physically active population: a systematic review. *Nutrients* 2020;12(2):501.
518. Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. *J Med Food* 2016;19(8):717–29.
519. Onakpoya IJ, Spencer EA, Perera R, et al. Effectiveness of curcuminoids in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized clinical trials. *Int J Rheum Dis* 2017;20(4):420–33.
520. Gaffey A, Slater H, Porritt K, et al. The effects of curcuminoids on musculoskeletal pain: a systematic review. *JBI Database Syst Rev Implement Rep* 2017;15(2):486–516.
521. Pakfetrat M, Basiri F, Malekmakan L, et al. Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. *J Nephrol* 2014;27(2):203–7.

522. European Medicines Agency. European Union herbal monograph on *Curcuma longa* L., rhizoma. 2018. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf)
523. Lombardi N, Crescioli G, Maggini V, et al. Acute liver injury following turmeric use in Tuscany: an analysis of the Italian Phytovigilance database and systematic review of case reports. *Br J Clin Pharmacol* 2020;Epub 2020 Jul 13.
524. Medsafe. Beware turmeric/curcumin containing products can interact with warfarin. 2018. At: <https://medsafe.govt.nz/safety/EWS/2018/Turmeric.asp>
525. Somasundaram S, Edmund N, Moore D, et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. *Cancer Res* 2002;62(13):3868–75.
526. Volak LP, Ghirmai S, Cashman JR, et al. Curcuminoids inhibit multiple human cytochromes P450 (CYP), UDP-glucuronosyltransferase (UGT), and sulfotransferase (SULT) enzymes, while piperine is a relatively selective CYP3A4 inhibitor. *Drug Metab Dispos* 2008;36(8):1594–605.
527. Rasyid A, Rahman AR, Jaalam K, et al. Effect of different curcumin dosages on human gall bladder. *Asia Pac J Clin Nutr* 2002;11(4):314–18.
528. Tang M, Larson-Meyer DE, Liebman M. Effect of cinnamon and turmeric on urinary oxalate excretion, plasma lipids, and plasma glucose in healthy subjects. *Am J Clin Nutr* 2008;87(5):1262–7.
529. Lopes-Rodrigues V, Sousa E, Vasconcelos MH. Curcumin as a modulator of P-glycoprotein in cancer: challenges and perspectives. *Pharmaceuticals (Basel)* 9(4):71.
530. Kushihara H, Furuie H, Inano A, et al. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. *Br J Pharmacol* 2012;166(6):1793–803.
531. Eke-Okoro U, Raffa R, Ergolizzi J, et al. Curcumin in turmeric: basic and clinical evidence for a potential role in analgesia. *J Clin Pharm Ther* 2018;43(4):460–6.
532. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med* 1998;64(4):353–6.
533. Leach MJ, Page AT. Herbal medicine for insomnia: a systematic review and meta-analysis. *Sleep Med Rev* 2015;24:1–12.
534. Miyasaka LS, Atallah ÁN, Soares B. Valerian for anxiety disorders. *Cochrane Database of Systematic Reviews* 2006, Issue 4.
535. European Medicines Agency. European Union herbal monograph on *Valeriana officinalis* L., radix. 2016. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-valeriana-officinalis-l-radix_en.pdf)
536. Toovey OT, Redmond IR, Makris N. Acute severe hyponatraemia secondary to polydipsia and associated herbal remedy use. *BMJ Case Reports* 2016;bcr2016216348.
537. Therapeutic Goods Administration. Valerian (*Valeriana officinalis*): safety advisory—potential for liver injury. 2020. At: [www.tga.gov.au/alert/valerian-valeriana-officinalis](http://www.tga.gov.au/alert/valerian-valeriana-officinalis)
538. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. *JAMA* 1998;280(18):1566–7.
539. The drug database for acute porphyria. 2007. At: [www.drugs-porphyrria.org/languages/UnitedKingdom/s1.php?l=gbr](http://www.drugs-porphyrria.org/languages/UnitedKingdom/s1.php?l=gbr)
540. Mohamed MF, Frye RF. Effects of herbal supplements on drug glucuronidation: review of clinical, animal, and in vitro studies. *Planta Med* 2011;77(4):311–21.

541. European Medicines Agency. European Union herbal monograph on *Salix* [various species including *S. purpurea* L., *S. daphnoides* Vill., *S. fragilis* L.], cortex. 2017. At: [www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-salix-various-species-including-s-purpurea-l-s-daphnoides-vill\\_en.pdf](http://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-salix-various-species-including-s-purpurea-l-s-daphnoides-vill_en.pdf)

542. Oltean H, Robbins C, vanTulder MW. Herbal medicine for low-back pain. *Cochrane Database of Systematic Reviews* 2014, Issue 12.

543. Krivoy N, Pavlotzky E, Chrubasik S, et al. Effect of salicis cortex extract on human platelet aggregation. *Planta Med* 2001;67(3):209–12.

544. Therapeutic Goods Administration. Required Advisory Statements for Medicine Labels (RASML) No. 3. 2017. At: [www.tga.gov.au/publication/required-advisory-statements-medicine-labels-rasml](http://www.tga.gov.au/publication/required-advisory-statements-medicine-labels-rasml)